Carilion Clinic
Roanoke, Virginia, 24014, United States
Location status: Recruiting
NCT Number: NCT05283850
The Carilion Clinic and Virginia Tech Carilion School of Medicine, in conjunction with Roanoke Fire-EMS, Botetourt County Department of Fire & EMS and Salem Fire-EMS, are studying the outcomes of patients experiencing Pulseless Electrical Activity (PEA). PEA refers to a type of cardiac arrest in which there is normal electrical activity in the heart however the heart still fails to contract to generate a pulse. Without heart contractions, which normally generates a pulse, the brain and other important organs fail to receive blood and oxygen. Unfortunately, the majority (97.3%) of patients that experience this rhythm do not survive and most don't even make it to the hospital. This study is trying to determine if the administration of a High Calcium, Low Sodium (HCLS) fluid in pre-hospital care will improve the chances of survival.
Generally, a sodium (salt) solution is provided to patients experiencing cardiac arrest. Studies have shown that lower sodium and higher calcium content may activate certain parts of the heart cells required to generate a pulse under PEA conditions.
This study is a double-blind, prospective, clinical trial. PEA patients will randomly receive either routine fluid therapy (salt solution) or a HCLS solution. While HCLS solution is not the standard fluid used by EMS providers responding to PEA, it is composed of FDA approved components and is occasionally used by EMS providers at their discretion in treating PEA. It is predicted that HCLS will either improve PEA survival or deliver similar outcomes as routine treatment. All patients will receive standard, high quality cardiac arrest and post-cardiac arrest care regardless of assigned treatment group.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2 / Phase 3
Roanoke, Virginia, 24014, United States
Location status: Recruiting
Pursuant to a Waiver of Informed Consent, this investigation will automatically enroll all eligible PEA patients treated by Roanoke Fire-EMS, Botetourt County Department of Fire & EMS and/or Salem Fire-EMS systems.
Once patients are enrolled, they will be de-facto randomized into one of two groups: control High Calcium-High Sodium (HCHS) or interventional High Calcium-Low Sodium (HCLS). Supervisors will have on their trucks, numbered-but-otherwise-blinded bags of half-normal saline or normal saline solution. The bags will be numbered, recorded and randomized by this study's investigators. Supervisors, when providing care, will universally administer 1g unblinded CaCl2 and then subsequently chose a crystalloid fluid set to use from their trucks randomly. The crystalloid will be administered as a wide open IV drip at a rate of at least 1000ml/hour, depending on gauge size, for as long as fluids are indicated for, likely resulting in a crystalloid dose of 0.5-2(L) liters. Each bag-set will have two bags of the same blinded unit to allow for treatment with up to (2L) 2 liters of fluid for a patient. Explicitly, all enrolled patients will be receiving calcium, it is only the crystalloid fluid (normal saline vs half-normal saline) that will differ. HCLS treatment was designed to be hyponatremic compared to normal saline (while both groups in this trial will be hypercalcemic compared to pure normal saline PEA therapy) in order to initiate low sodium inotropy.
The contents of the bag will be blinded to the supervisor. Neither the patient nor the supervisor will know which treatment was given thus ensuring double-blinding. Further, by randomly choosing a bag with no knowledge of its contents, the treatment will effectively be randomized. Both groups will otherwise receive current routine Advanced Cardiac Life Support and either standard post-arrest care or standard termination of care. Per Roanoke Fire-EMS, Botetourt County Department of Fire & EMS and Salem Fire-EMS standard protocol, only patients who undergo ROSC on scene will be transported to a hospital.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
Other names: (NDC) National Drug Code NDC 0264-7800-00 and NDC 0409-4928-11
Normal saline IV drip and 1g IV bolus Calcium Chloride.
Other names: NDC NDC 0264-7802-00 and NDC 0409-4928-11
Time frame: Up to 1 hour
ROSC sustained until arrival at the emergency department and transfer of care to medical staff at the receiving hospital?
Time frame: Through resuscitation efforts up to 1 hour after arrival to (ED) Emergency Department
Did the patient achieve ROSC at any point during the resuscitation attempt?
Time frame: Up to 30 days after admission to (ED) Emergency Department
Did the patient survive to hospital discharge?
Time frame: Up to 30 days after admission to ED
(CPC) Cerebral Performance Category Score and/or (mRS) modified Rankin Score at hospital discharge?
Time frame: Up to 12 hour after admission to the (ED) Emergency Department
All (BMP) Basic Metabolic Panel values will be collected, but there is a particular emphasis on serum sodium and calcium values.
Contact information is provided by the study sponsor or research team.
Carol Bernier
Other
A Prospective, Pre-Hospital Comparison of Normal Saline Versus Half-Normal Saline, After Universal Calcium Chloride Administration, to Improve Outcomes in Pulseless Electrical Activity Patients
Acronym: SPEAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06071910
Arrhythmias, Cardiac, Cardiac Arrest
Norwich, United Kingdom
View Trial DetailsNCT01446471
Asystole, Cardiac Arrest
Newark, Delaware, United States
View Trial DetailsNCT07434726
Cardiac Arrest, Cardiovascular Diseases
Bern, Switzerland
View Trial DetailsNCT06672159
Arrhythmias, Cardiac, Cardiac Arrest
Trondheim, Norway
View Trial Details